Bristol and Glaxo’s oncology deals vault into the top five
Two huge up-front fees this week, for an anti-Tigit MAb and an antibody-drug conjugate, show that early-stage oncology assets are still hot.
A surprise Keytruda approval, and what it means for biotech
A Her2-positive cancer is the setting for a Keytruda triplet that could influence the trial design of some immune-stimulating agents.
Bristol bets on cytokines again
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
Smaller groups await Bristol-Myers Squelgene fallout
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?